Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics a

From: Subclinical inflammation on MRI of hand and foot of anticitrullinated peptide antibody–negative arthralgia patients at risk for rheumatoid arthritis

Characteristics Symptom-free controls ACPA-negative arthralgia ACPA-negative RA
(n = 19) (n = 64) (n = 20)
Mean age, yr (SD) 46.2 (11.8) 41.9 (14.3) 58.7 (14.5)
Females, n (%) 15 (78.9) 46 (71.9) 11 (55.0)
Positive family history of RA, n (%) N/A 25 (39.1) 4 (20.0)
Median symptom duration at time of inclusion, wk (IQR) N/A 13.4 (8.4 to 26.4) 17.6 (11.5 to 25.9)
Gradual symptom onset, n (%) N/A 48 (75.0) 12 (60.0)
Initial symptom localization, n (%) N/A   
   Upper extremities, n (%)   47 (73.4) 10 (50.0)
   Lower extremities, n (%)   2 (3.1) 4 (20.0)
   Upper and lower extremities, n (%)   15 (23.4) 6 (30.0)
Symmetrical localization, n (%) N/A 46 (71.9) 13 (65.0)
Median morning stiffness, min (IQR) N/A 45 (15 to 90) 120 (30 to 120)
Median tender joint count in 68 joints (IQR) 0 5.5 (3 to 10.8) 12 (4.8 to 17.8)
Median swollen joint count 66 joints (IQR) 0 0 6 (4 to 11)
ACPA positivity (>7.0 IU/ml), n (%) N/A 0 0
IgM RF positivity (>3.5 IU/ml), n (%) N/A 9 (14.1) 3 (15.0)
Increased CRP level (>10 mg/L), n (%) N/A 10 (15.6) 11 (55.0)
  1. aACPA, Anticitrullinated peptide antibody; CRP, C-reactive protein; IQR, Interquartile range; IgM RF, Immunoglobulin M rheumatoid factor; N/A, Not applicable; RA, Rheumatoid arthritis; SD, Standard deviation.